When will generic bedaquiline become available in developing countries?

How soon can generic bedaquiline reach patients in low-income markets?

Bedaquiline generics are expected to enter markets in developing countries starting in 2025. This timeline depends on the expiration of key patents in major supplying countries and the pace of regulatory approvals for versions produced by Indian manufacturers.

Why are patents still blocking earlier access?

The primary composition-of-matter patent for bedaquiline expires in 2023 in the United States, but secondary patents covering manufacturing processes and formulations extend protection in India and other exporting countries until at least 2027. These secondary patents are the main reason generic versions have not launched earlier in high-burden tuberculosis regions.

How are Indian manufacturers preparing for launch?

Several Indian generic companies have already filed dossiers with the World Health Organization Prequalification program and with national regulators in high-TB-burden countries. Once the secondary patents clear, these manufacturers can complete bioequivalence studies and scale up production quickly, often within six to twelve months.

What role do voluntary licenses play?

A voluntary license signed between Johnson & Johnson and the Stop TB Partnership’s Global Drug Facility allows generic production for 135 low- and middle-income countries. The license includes technology transfer and sets a ceiling price of roughly $900 for a six-month course, which generic makers must undercut to win large procurement tenders.

When will price drops actually reach national programs?

Historical data on other TB drugs show that once the first generic is prequalified, prices fall 60–80 percent within two years. National TB programs in countries such as South Africa, India, and Indonesia are expected to switch to generic bedaquiline once at least two suppliers meet WHO quality standards.

Can biosimilars enter before patent expiry?

No true biosimilars exist for bedaquiline because it is a small-molecule drug, not a biologic. However, regulatory authorities in some countries allow “similar” generic applications under abbreviated pathways once the primary patent lapses, provided manufacturing and stability data are submitted.

What happens if secondary patents are challenged successfully?

At least two Indian generic firms have filed post-grant oppositions against the remaining formulation patents. If these challenges succeed in 2024, generic launch could move forward by late 2024 in markets covered by the voluntary license, shaving roughly a year off the current forecast.

DrugPatentWatch.com